Execute GLP-1 trials with precision: Streamline operations for rapid and reliable enrollment This article is part of Parexel's "Navigating to 2030" playbook series on differentiating next-generation obesity therapies
Before-and-after results are real, but gradual, structural, and built on consistency rather than an overnight transformation
Compounded GLP-1 medications are significantly cheaper than brand-name options across the board
The STEP-1 body-composition substudy (n=140 DXA cohort) of semaglutide (Wegovy at 2.4 mg weekly) reported fat-free mass loss of approximately 6.9 kg over 68 weeks, accounting for approximately 45% of total weight loss based on the body-composition substudys own arithmetic and the Conte 2024 systematic review [6, 7]
The agency, in its Monday announcement, noted it prioritizes assessment of generic drug applications for drugs in shortage to help improve patient access to these medications. Dr
An 8.7% reduction exceeds what most lifestyle interventions achieve